natgillin/translations-raw huggingface dataset:
(such as: compulsive shopping, pathological gambling, hypersexuality, binge eating) 
vedenjski simptomi motenj nadzora impulzov in kompulzije1 (na primer: kompulzivno nakupovanje, patološko hazardiranje, hiperseksualnost, prenajedanje)
Each tablet contains 1.0 mg pramipexole dihydrochloride monohydrate equivalent to 0.7 mg pramipexole. 
Ena tablete vsebuje 0,7 mg pramipeksola v obliki 1,0 mg pramipeksolijevega diklorida monohidrata.
If you take more Pramipexole Accord than you should If you accidentally take too many tablets, 
Če ste vzeli večji odmerek zdravila Pramipeksol Accord , kot bi smeli Če ste nenamerno vzeli več tablet, kot bi smeli: - nemudoma vprašajte za nasvet svojega zdravnika ali v najbližjo bolnišnico, - boste morda izkusili bruhanje, nemir ali katerega od neželenih učinkov, opisanih v poglavju 4
In the absence of human data, Pramipexole Accord should not be used during breast-feeding. 
Če je mogoče, zdravila Pramipeksol Accord med dojenjem ne dajemo, ker ni podatkov za človeka.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Accord Healthcare S.L.U. 
Imetnik dovoljenja za promet z zdravilom in izdelovalec:
Gastrointestinal disorders nausea constipation vomiting 
Bolezni prebavil navzea zaprtost bruhanje
Total Daily Dose (mg of base) 
Teden Odmerek (mg)
1 dose (0.5 ml) contains approximately: Human Papillomavirusa Type 6 L1 proteinb,c aHuman Papillomavirus = HPV bL1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology. 
bL1 protein v obliki virusu podobnih delcev, pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae CANADE 3C-5 (sev 1895)) cadsorbiran na amorfni aluminijev hidroksifosfat sulfat kot adjuvans (225 mikrogramov Al)
1 pre-filled syringe + 1 needle 
1 napolnjena injekcijska brizga + 1 igla
1 pre-filled syringe + 2 needles 
1 napolnjena injekcijska brizga + 2 igli
Strength Pharmaceutical Form 
Številka EU Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
Content (concentratio n) 
ahumani papilomavirus = HPV
This summary was last updated in 09-2008. 
Povzetek je bil nazadnje posodobljen 09-2008.
The marketing authorisation was renewed on 18 September 2003 and on 18 September 2008. 
Dovoljenje za promet z zdravilom je bilo obnovljeno 18. septembra 2003 in 18. septembra 2008.
It is available as 250 mg sachets, each containing 12.5 mg imiquimod (5%). 
Na voljo je v 250miligramskih vrečkah, od katerih vsaka vsebuje 12,5 mg imikvimoda (5 %).
Other information about Aldara: 
Druge informacije o zdravilu Aldara:
It is used when other treatments such as cryotherapy (freezing) cannot be used. 
Uporablja se, kadar drugačnega zdravljenja, kot je na primer krioterapija (zmrzovanje), ni mogoče uporabiti.
Aldara is used in adults to treat the following skin diseases: 
Zdravilo Aldara se uporablja pri odraslih za zdravljenje naslednjih kožnih obolenj:
• small basal cell carcinomas (slow-growing types of skin cancer); 
• majhnih karcinomov bazalnih celic (počasi rastočih vrst kožnega raka);
The marketing authorisation holder is Meda AB. 
Imetnik dovoljenja za promet z zdravilom je družba Meda AB.
In all studies, Aldara was more effective than placebo. 
Zdravilo Aldara je bilo v vseh študijah učinkovitejše od placeba.
The European Commission granted a marketing authorisation valid throughout the European Union for Aldara on 18 September 1998. 
Evropska komisija je dovoljenje za promet z zdravilom Aldara, veljavno po vsej Evropski uniji, odobrila dne 18. septembra 1998.
The Committee recommended that Aldara be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Aldara odobri dovoljenje za promet.
These substances help to kill the viruses that cause warts or the abnormal cells in the skin that develop into skin cancer or keratoses. 
Te snovi pomagajo pri uničevanju virusov, ki povzročajo bradavice ali nenormalne celice v koži, ki se lahko razvijejo v kožnega raka ali keratoze.
When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon. 
Ko se imikvimod nanese na kožo, lokalno deluje na imunski sistem tako, da sproži sproščanje citokinov, vključno z interferoni.
What benefit has Aldara shown during the studies? 
Kakšne koristi je zdravilo Aldara izkazalo med študijami?
Aldara should not be used in people who may be hypersensitive (allergic) to imiquimod or any of the other ingredients. 
Zdravila Aldara ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) imikvimod ali katero koli drugo sestavino zdravila.
The cream is applied in a thin layer to the affected areas of skin before sleeping, so that it remains on the skin for a suitable length of time (about eight hours) before being washed off. For further information, see the Package Leaflet. 
Krema se pred spanjem v tanki plasti nanaša na prizadeta mesta na koži, tako da ostane na koži primerno dolgo časa (približno osem ur), preden se spere.
• actinic keratoses of the face and scalp (precancerous, abnormal skin growths that develop after too much exposure to sunlight), in patients whose immune system is working normally. 
• aktiničnih keratoz obraza in lasišča (predrakave nenormalne kožne tvorbe, ki se razvijejo ob prekomernem izpostavljanju sončni svetlobi) pri bolnikih, katerih imunski sistem deluje normalno.
• For small basal cell carcinomas, the cream is applied five times a week for six weeks. 
• Pri majhnih karcinomih bazalnih celic se kremo v obdobju šestih tednov nanaša po petkrat na teden.
In all studies, Aldara was compared with placebo (the same cream but without the active substance). 
V vseh študijah so zdravilo Aldara primerjali s placebom (enako kremo, ki pa ni vsebovala zdravilne učinkovine).
The Committee for Medicinal Products for Human Use (CHMP) decided that Aldara's benefits are greater than its risks for the treatment of external genital and perianal warts (condylomata acuminata), small basal cell carcinomas and nonhyperkeratotic, nonhypertrophic actinic keratoses in immunocompetent adult patients when other topical treatment options are contraindicated or less appropriate. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Aldara pri zdravljenju zunanjih bradavic na spolovilu in v okolici zadnjične odprtine (condylomata acuminata), majhnih karcinomov bazalnih celic in nehiperkeratotičnih, nehipertrofičnih aktiničnih keratoz pri odraslih bolnikih z normalnim delovanjem imunskega sistema, kadar so možnosti uporabe drugačnega lokalnega zdravljenja kontraindicirane ali manj primerne, večje od z njim povezanih tveganj.
The main measure of effectiveness was the number of patients with total clearance of the tumours after 12 weeks. 
Glavno merilo učinkovitosti je bilo število bolnikov s popolno odstranitvijo tumorjev po 12 tednih.
The main measure of effectiveness was the number of patients whose keratoses had cleared after one or two four-week courses of treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov, katerih keratoze so izginile po enem ali dveh štiritedenskih obdobjih zdravljenja.
• warts on the genitals and around the anus; 
• bradavic na spolovilu in okoli zadnjične odprtine;
The most common side effect with Aldara (seen in more that 1 patient in 10) is a reaction at the site of application of the cream (pain or itching). 
Najpogostejši neželeni učinek zdravila Aldara (opažen pri več kot 1 bolniku od 10) je reakcija na mestu nanosa kreme (bolečina ali srbenje).
For the full list of all side effects reported with Aldara, see the Package Leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Aldara, glejte navodilo za uporabo.
The active substance in Aldara cream, imiquimod, is an immune response modifier. 
Zdravilna učinkovina v kremi Aldara, imikvimod, je sredstvo za spreminjanje imunskega odziva telesa.
What is the risk associated with Aldara? 
Kakšna tveganja so povezana z uporabo zdravila Aldara?
• Aldara has also been studied in 724 patients with small basal cell carcinomas in two studies where patients were treated for six weeks, and used Aldara or placebo either five times a week or every day. 
• Zdravilo Aldara so preizkušali tudi pri 724 bolnikih z majhnimi karcinomi bazalnih celic v dveh študijah, v katerih so bolnike zdravili šest tednov, uporabljali pa so zdravilo Aldara ali placebo,
Why has Aldara been approved? 
Zakaj je bilo zdravilo Aldara odobreno?
The number of times Aldara is applied and the duration of treatment depend on the condition being treated: 
Število nanosov kreme Aldara in trajanje zdravljenja sta odvisna od obolenja, ki se ga zdravi.
This means that it uses the immune system, the body's natural defences, to bring about its effect. 
To pomeni, da krema doseže svoj učinek z delovanjem na imunski sistem, naravno obrambo telesa.
The main measure of effectiveness was the number of patients with total clearance of treated warts. 
Glavno merilo učinkovitosti je bilo število bolnikov s popolno odstranitvijo zdravljenih bradavic.
Aldara is a cream containing the active substance imiquimod. 
Zdravilo Aldara je krema, ki vsebuje zdravilno učinkovino imikvimod.
• For genital warts, Aldara is applied three times a week for up to 16 weeks. 
• Pri bradavicah na spolovilu se zdravilo Aldara nanaša trikrat na teden, pri čemer zdravljenje traja največ 16 tednov.
The full EPAR for Aldara is available here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aldara je na voljo tukaj.
• Aldara has been studied in 923 patients with genital warts in four main studies lasting 16 weeks. 
• Zdravilo Aldara so v štirih glavnih študijah, ki so trajale 16 tednov, preizkušali pri 923 bolnikih z bradavicami na spolovilu.
• In the treatment of genital warts, the total clearance rate across the four main studies was 15 to 52% in the Aldara-treated patients, compared with 3 to 18% in the placebo-treated patients. 
• Pri zdravljenju bradavic na spolovilu je stopnja popolne odstranitve v štirih glavnih študijah znašala 15 do 52 % pri bolnikih, ki so se zdravili z zdravilom Aldara, v primerjavi s 3 do 18 % pri bolnikih, ki so se zdravili s placebom.
• When the results of the two studies in basal cell carcinoma were looked at together, total clearance was seen in 66 to 80% of Aldara-treated patients compared with 0 to 3% in the placebo group. 
• Ob združitvi rezultatov dveh študij pri majhnih karcinomih bazalnih celic so popolno odstranitev ugotovili pri 66 do 80 % bolnikov, ki so se zdravili z zdravilom Aldara, v primerjavi z 0 do 3 % v skupini, ki je prejemala placebo.
• In actinic keratoses, complete clearance after one or two courses of treatment was seen in 54 and 55% of Aldara-treated patients in the two studies, compared with 15 and 2% in the placebo-treated patients. 
• Pri aktiničnih keratozah so v dveh študijah popolno odstranitev po enem ali dveh obdobjih zdravljenja ugotovili pri 54 in 55 % bolnikov, ki so se zdravili z zdravilom Aldara, v primerjavi s 15 in 2 % pri bolnikih, ki so prejemali placebo.
• For actinic keratoses, it is applied three times a week, for one or two four-week courses, with four weeks between courses. 
• Pri aktiničnih keratozah se krema nanaša trikrat na teden v enem ali dveh štiritedenskih obdobjih zdravljenja, pri čemer je med obema obdobjema zdravljenja treba narediti štiri tedne premora.
• Aldara has also been studied in patients with actinic keratoses in two studies involving a total of 505 patients. 
Zdravilo Aldara so v dveh študijah, v kateri je bilo skupno vključenih 505 bolnikov, preizkušali tudi pri bolnikih z aktiničnimi keratozami.
What is Aldara? 
Kaj je zdravilo Aldara?
What is Aldara used for? 
Za kaj se zdravilo Aldara uporablja?
How does Aldara work? 
Kako zdravilo Aldara deluje?
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ALDARA EPAR summary for the public 
Povzetek EPAR za javnost
How has Aldara been studied? 
Kako je bilo zdravilo Aldara raziskano?
How is Aldara used? 
Kako se zdravilo Aldara uporablja?
However this risk is considered small as patients take only one dose of the medicine and are supervised by their doctor. 
Vendar se to tveganje šteje za majhno, saj bolniki vzamejo samo en odmerek zdravila in jih nadzoruje njihov zdravnik.
The recommended dose is 0.5 mg per kg body weight which the patient should take once. 
Priporočeni odmerek zdravila je 0,5 mg na kilogram telesne mase, ki ga mora bolnik zaužiti naenkrat.
Overall, the side effects were mostly mild and short-lasting, with no need for a specific treatment. 
Na splošno so neželeni učinki večinoma blagi in kratkotrajni brez potrebe po posebnem zdravljenju.
Further information on Macimorelin Aeterna Zentaris can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/macimorelin-aeterna-zentaris. 
Nadaljnje informacije o zdravilu Macimorelin Aeterna Zentaris so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/macimorelin-aeterna-zentaris.
The doctor then takes blood samples 45, 60 and 90 minutes later to see how much growth hormone the body has produced. 
Zdravnik nato 45, 60 in 90 minut kasneje odvzame vzorce krvi, da ovrednoti, koliko je telo proizvedlo rastnega hormona.
This means that, although Macimorelin Aeterna Zentaris might not diagnose all cases of disease, it can help to confirm presence of the disease. 
To pomeni, da čeprav zdravilo Macimorelin Aeterna Zentaris ne utegne diagnosticirati vseh primerov bolezni, lahko pripomore k potrditvi njene prisotnosti.
The study involved 166 adults who had either a high, intermediate or low likelihood of having growth hormone deficiency, or who were confirmed not to have growth hormone deficiency. 
V tej študiji je sodelovalo 166 odraslih, pri katerih je obstajala velika, srednja ali majhna verjetnost za pomanjkanje rastnega hormona oziroma pri katerih je bilo potrjeno, da jim ga ne primanjkuje.
In terms of safety, the main concern was that the medicine may change heart rhythm. 
Z vidika varnosti je bil glavni zadržek morebitna sprememba srčnega utripa zaradi jemanja zdravila.
It is used by doctors to diagnose growth hormone deficiency, a condition where the patient does not have enough growth hormone. 
Uporabljajo ga zdravniki za diagnosticiranje pomanjkanja rastnega hormona, tj. obolenja, pri kateri bolnik nima dovolj rastnega hormona.
It is not used to treat patients with the condition. 
Zdravilo se ne uporablja za zdravljenje te bolezni.
Overall, 94% of people who tested negative for growth hormone deficiency with ITT also tested negative with Macimorelin Aeterna Zentaris; 74% of people who tested positive with ITT also tested positive with Macimorelin Aeterna Zentaris. 
Na splošno je imelo 94 % ljudi, ki so imeli negativen test ITT glede pomanjkanja rastnega hormona, negativen test tudi z zdravilom Macimorelin Aeterna Zentaris; 74 % ljudi, ki so imeli pozitiven test ITT, je imelo pozitiven rezultat tudi z zdravilom Macimorelin Aeterna Zentaris.
EMA considered that it is a priority to avoid over-diagnosis of adult growth hormone deficiency and that Macimorelin Aeterna Zentaris helps confirm positive diagnosis and so avoid unnecessary treatment of patients with a false positive test result. 
Agencija EMA je menila, da se je treba izogniti pretiranemu diagnosticiranju pomanjkanja rastnega hormona pri odraslih in da zdravilo Macimorelin Aeterna Zentaris pomaga potrditi pozitivno diagnozo in tako preprečiti nepotrebno zdravljenje bolnikov z lažno pozitivnim rezultatom testa.
On the whole, Macimorelin Aeterna Zentaris has fewer side effects than the comparator test, which temporarily lowers the level of sugar in the blood. 
Na splošno ima zdravilo Macimorelin Aeterna Zentaris manj neželenih učinkov kot primerjalni test, ki začasno zniža raven sladkorja v krvi.
The most common side effects with Macimorelin Aeterna Zentaris (which may affect up to 1 in 10 people) are a bitter or metallic taste, tiredness, headache, nausea (feeling sick), dizziness, diarrhoea and feeling hot. Macimorelin Aeterna Zentaris may also cause a change in heart rhythm. 
Najpogostejši neželeni učinki zdravila Macimorelin Aeterna Zentaris (ki lahko prizadenejo največ 1 osebo od 10) so grenek ali kovinski okus, utrujenost, glavobol, navzeja (siljenje na bruhanje), omotica, driska in občutek vročine.
The level of growth hormone in the blood is then measured and indicates whether or not the body is able to produce growth hormone. 
Nato se izmeri raven rastnega hormona v krvi, s čimer se ugotovi, ali lahko telo samo proizvaja rastni hormon ali ne.
EMA therefore decided that Macimorelin Aeterna Zentaris's benefits are greater than its risks and it can be authorised for use in the EU. 
Agencija je zaključila, da so koristi zdravila Macimorelin Aeterna Zentaris večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Macimorelin Aeterna Zentaris have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Macimorelin Aeterna Zentaris upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Macimorelin Aeterna Zentaris are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Macimorelin Aeterna Zentaris, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
As for all medicines, data on the use of Macimorelin Aeterna Zentaris are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Macimorelin Aeterna Zentaris stalno spremljajo.
What measures are being taken to ensure the safe and effective use of Macimorelin Aeterna Zentaris? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Macimorelin Aeterna Zentaris?
For more information about using Macimorelin Aeterna Zentaris, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Macimorelin Aeterna Zentaris glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Macimorelin Aeterna Zentaris and why it is authorised in the EU 
Pregled zdravila Macimorelin Aeterna Zentaris in zakaj je odobreno v EU
Among them, 140 were tested with both Macimorelin Aeterna Zentaris and ITT. 
Pri 140 od teh bolnikov so opravili testiranje z zdravilom Macimorelin Aeterna Zentaris in testom ITT.
The active substance in Macimorelin Aeterna Zentaris, macimorelin, stimulates the release of growth hormone into the blood by activating receptors (targets) found on cells in the pituitary gland, a gland located at the base of the brain. 
Učinkovina v zdravilu Macimorelin Aeterna Zentaris, macimorelin, spodbuja sproščanje rastnega hormona v kri z aktiviranjem receptorjev (prijemališč), ki so na celicah hipofize, tj. žleze na dnu možganov.
Why is Macimorelin Aeterna Zentaris authorised in the EU? 
Zakaj je bilo zdravilo Macimorelin Aeterna Zentaris odobreno v EU?
Macimorelin Aeterna Zentaris can only be obtained with a prescription and its use must be supervised by a healthcare professional experienced in diagnosing growth hormone deficiency. 
Predpisovanje in izdaja zdravila Macimorelin Aeterna Zentaris je le na recept, njegovo uporabo pa mora nadzorovati zdravstveni delavec z izkušnjami z diagnosticiranjem pomanjkanja rastnega hormona.
Macimorelin Aeterna Zentaris is a medicine used to test the ability of the body to produce growth hormone. 
Zdravilo Macimorelin Aeterna Zentaris se uporablja za preverjanje sposobnosti telesa za tvorjenje rastnega hormona.
Other information about Macimorelin Aeterna Zentaris 
Druge informacije o zdravilu Macimorelin Aeterna Zentaris
What is Macimorelin Aeterna Zentaris and what is it used for? 
Kaj je zdravilo Macimorelin Aeterna Zentaris in za kaj se uporablja?
Macimorelin Aeterna Zentaris was compared with another test commonly used to diagnose growth hormone deficiency, called insulin tolerance test (ITT), in one main study. 
V eni glavni študiji so zdravilo Macimorelin Aeterna Zentaris primerjali z drugim testom, ki se običajno uporablja za diagnosticiranje pomanjkanja rastnega hormona, imenovanega test tolerance insulina (ITT).
For the full list of side effects and restrictions with Macimorelin Aeterna Zentaris, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev zdravila Macimorelin Aeterna Zentaris glejte navodilo za uporabo.
What are the risks associated with Macimorelin Aeterna Zentaris? 
Kakšna tveganja so povezana z zdravilom Macimorelin Aeterna Zentaris?
What benefits of Macimorelin Aeterna Zentaris have been shown in studies? 
Kakšne koristi je zdravilo Macimorelin Aeterna Zentaris izkazalo v študijah?
Macimorelin Aeterna Zentaris is available as granules that are dissolved in water and taken by mouth. 
Zdravilo Macimorelin Aeterna Zentaris je na voljo v obliki zrnc, ki jih je treba raztopiti v vodi in zaužiti peroralno.
Macimorelin Aeterna Zentaris contains the active substance macimorelin. 
Zdravilo Macimorelin Aeterna Zentaris vsebuje zdravilno učinkovino macimorelin.
Macimorelin Aeterna Zentaris gave a similar number of negative test results for growth hormone deficiency as a comparator test; however, it gives fewer positive test results than the comparator. 
Zdravilo Macimorelin Aeterna Zentaris je imelo podobno število negativnih rezultatov na test pomanjkljivosti rastnega hormona kot primerjalni test.
How is Macimorelin Aeterna Zentaris used? 
Kako se zdravilo Macimorelin Aeterna Zentaris uporablja?
How does Macimorelin Aeterna Zentaris work? 
Kako zdravilo Macimorelin Aeterna Zentaris deluje?
At the final analysis, 1,653 deaths were reported. 
V končni analizi so poročali o 1.653 smrtnih primerih.
Your injection could take about 15 seconds. 
Injiciranje lahko traja približno 15 sekund.
The healthcare professional's educational material should contain the following key elements: 
Izobraževalno gradivo za zdravstvenega delavca mora vsebovati naslednje ključne elemente:
There may be local guidelines for disposal. 
Morda obstajajo lokalne smernice za odlaganje.
study (study 20010184). 
TREAT (študija 20010184).
This may vary depending on whether you are an adult or a child. 
Odmerek se lahko razlikuje glede na to, ali ste odrasla oseba ali otrok.
• Serious allergic reactions which may include: 
• Resne alergijske reakcije, ki lahko vključujejo:
To give yourself an injection you will need: 
Da si boste dali injekcijo, potrebujete:
Please discuss this with your doctor. 
Prosimo, da se o tem posvetujete z zdravnikom.
A risk to the suckling child cannot be excluded. 
Tveganja za dojenčka ne moremo izključiti.
In some cases, your doctor may recommend that you take iron supplements. 
V nekaterih primerih vam zdravnik lahko svetuje jemanje dodatkov železa.
• think you may be pregnant; or 
• mislite, da ste noseči; ali
30 minutes 
30 minut
Do not administer more than one dose. 
Ne aplicirajte več kot enega odmerka.
No alteration of fertility was detected. 
Sprememb plodnosti niso odkrili.
The instructions for use, handling and disposal are given in section 6.6. 
Navodila za uporabo, ravnanje z zdravilom in odlaganje so navedena v poglavju 6.6.
A reticulocyte count should be considered as part of the evaluation. 
Določanje števila retikulocitov mora biti del ocenjevanja.
Your blood pressure will also be checked regularly, particularly at the beginning of your treatment. 
Redno vam bo preverjal tudi krvni tlak, še posebej na začetku zdravljenja.
If it is cloudy or there are particles in it, you must not use it. 
Če je motna ali so v njej delci, je ne smete uporabiti.
Because it will take your body some time to make more red blood cells, it will be about four weeks before you notice any effect. 
Ker telo za nastanek več rdečih krvnih celic potrebuje nekaj časa, bodo minili približno štirje tedni, preden boste opazili kakšen učinek.
Guidance is given separately for adult and paediatric patients. 
Smernice so navedene ločeno za odrasle in pediatrične bolnike.